Statin-associated peripheral neuropathy: Review of the Literature

Pharmacotherapy

Volumn 24, Issue 9, 2004, Pages 1194-1203

  Chong, Pang H ^a,b,d   Boskovich, Alexandra ^d   Stevkovic, Natasa ^a   Bartt, Russell E ^a,c  

^a Jr Hospital   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^c RUSH MEDICAL COLLEGE   (United States)

^d MIDWESTERN UNIVERSITY   (United States)

Author keywords

HMG CoA reductase inhibitors; Peripheral neuropathy; Statins

Indexed keywords

2',3' DIDEOXYNUCLEOSIDE DERIVATIVE; AMIODARONE; AMITRIPTYLINE; ANTILIPEMIC AGENT; ATORVASTATIN; CHLORAMPHENICOL; DAPSONE; DISULFIRAM; FLUINDOSTATIN; GLUTETHIMIDE; GOLD; HEAVY METAL; HYDRALAZINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ISONIAZID; LITHIUM; METRONIDAZOLE; MEVINOLIN; MISONIDAZOLE; NICOTINIC ACID; NITROFURANTOIN; PERHEXILINE; PHENYTOIN; PRAVASTATIN; PYRIDOXINE; ROSUVASTATIN; SIMVASTATIN; THALIDOMIDE; UNINDEXED DRUG; VINCRISTINE;

ALGORITHM; CASE REPORT; CHOLESTEROL METABOLISM; CLINICAL PRACTICE; CLINICAL TRIAL; COHORT ANALYSIS; DISEASE PREDISPOSITION; DRUG INDUCED DISEASE; DRUG SAFETY; DRUG USE; DRUG WITHDRAWAL; ELECTROMYOGRAPHY; ENZYME INHIBITION; HIGH RISK POPULATION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; INCIDENCE; MAJOR CLINICAL STUDY; NEUROPATHY; NEUROTOXICITY; PARESTHESIA; PERIPHERAL NEUROPATHY; POLYNEUROPATHY; PRACTICE GUIDELINE; SHORT SURVEY;

ALGORITHMS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; PERIPHERAL NERVOUS SYSTEM DISEASES; RISK FACTORS;

EID: 4344658296     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.24.13.1194.38084     Document Type: Short Survey

References (30)

1. Chong PH, Seeger JD, Franklin C. Clinically relevant differences between the statins: implications for therapeutic selection. Am J Med 2001;111:390-400.
2. Knopp RH. Drug treatment of lipid disorders. N Engl J Med 1999;341:498-511.
3. Blum CB. Comparison of the properties of four inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. Am J Cardiol 1994;73(suppl):3D-11.
4. Gaist D, Garcia Rodriguez LA, Huerta C, Hallas J, Sindrup SH. Are users of lipid-lowering drugs at increased risk of peripheral neuropathy? Eur J Clin Pharmacol 2001;56:931-3.
5. Gaist D, Jeppesen U, Andersen M, Garcia Rodriguez LA, Hallas J, Sindrup SH. Statins and risk of polyneuropathy: a case-control study. Neurology 2002;58:1333-7.
6. Chazerain P, Hayem G, Hamza S, Best C, Ziza JM. Four cases of tendinopathy in patients on statin therapy. Joint Bone Spine 2001;68:430-3.
7. Phan T, McLeod JG, Pollard JD, Peiris O, Rohan A, Halpern JP. Peripheral neuropathy associated with simvastatin. J Neurol Neurosurg Psychiatry 1995;58;625-8.
8. Ziajka PE, Wehmeier T. Peripheral neuropathy and lipid-lowering therapy. South Med J 1998;91:667-8.
9. Jeppesen J, Gaist D, Smith T, Sindrup SH. Statins and peripheral neuropathy. Eur J Clin Pharmacol 1999;54:835-8.
10. Silverberg C. Atorvastatin-inducted polyneuropathy. Ann Inter Med 2003;139:792-3.
11. Pfizer, Inc. Lipitor (atorvastatin) package insert. New York, NY; 2003.
12. Novartis Pharmaceuticals. Lescol (fluvastatin) package insert. East Hanover, NJ; 2003.
13. Merck & Co. Mevacor (lovastatin) package insert. West Point, PA; 1995.
14. Bristol-Myers Squibb Co. Pravachol (pravastatin) package insert. Princeton, NJ; 2003.
15. Merck & Co. Zocor (simvastatin) package insert. West Point, PA; 2003.
16. AstraZeneca LP Pharmaceuticals. Crestor (rosuvastatin) package insert. Wilmington, DE; 2003.
17. Bouldin TW. The peripheral nervous system. In: Rubin E, Farber JL, eds. Essential pathology. Philadelphia: JB Lippincott, Co., 1995:749-53.
18. Werner N, Nickenig G, Laufs U. Pleiotropic effects of HMG-CoA reductase inhibitors. Basic Res Cardiol 2002;97:105-16.
19. Jacobs MB. HMG-CoA reductase inhibitors therapy and peripheral neuropathy [letter]. Ann Intern Med 1994;120:970.
20. Walravens PA, Greene C, Frerman FE. Lovastatin, isoprenes and myopathy. Lancet 1989;2(8671):1097-8.
21. McManis PG, Windeback AJ, Kiziltan M. Neuropathy associated with hyperlipidemia. Neurology 1994;44:2185-6.
22. Drory VE, Groozman GB, Rubinstein A, Korczyn AD. Hypertriglyceridemia may cause a subclinical peripheral neuropathy. Electromyogr Clin Neurophysiol 1999;39:39-41.
23. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland coronary prevention group. N Engl J Med 1995;333:1301-7.
24. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996;335:1001-9.
25. Scandinavian Simvastatin Survival Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian simvastatin survival study. Lancet 1994;344:1383-9.
26. Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998;339:1349-57.
27. Downs JR, Clearfield M, Weis S, et al, for the AFCAPS/TexCAPS Research Group. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. JAMA 1998;279:1615-22.
28. Heart Protection Study Collaborative Group. MRGBHF heart protection study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomized placebo-controlled trial. Lancet 2002;360:7-22.
29. Lovastatin Study Groups I-IV. Lovastatin 5-year safety and efficacy study. Arch Intern Med 1993;153:1079-87.
30. Moriarty P. Using both "relative risk reduction" and "number needed to treat" in evaluating primary and secondary clinical trials of lipid reduction. Am J Cardiol 2001;87:1206-8.